ADVERTISEMENT

EAS 2022 — Are incretins the key to CVD prevention in the era of obesity and diabetes?

Pavankumar Kamat   |   Conference Report   |   26 May 2022
ADVERTISEMENT

In the opening CME session at EAS 2022 chaired by Lale Tokgözoğlu, Turkey and Kausik K. Ray, United Kingdom, experts discussed the role of incretin therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in atherosclerosis and their potential in preventing adverse cardiovascular outcomes in an era where the prevalence of obesity and...

          

March Challenge

Ends in 6d 13h
left
right

Topic Challenges

left
right